CCCC
C4 Therapeutics Inc
NASDAQ: CCCC · HEALTHCARE · BIOTECHNOLOGY
$2.83
+10.55% today
Updated 2026-04-30
Market cap
$281.02M
P/E ratio
—
P/S ratio
7.82x
EPS (TTM)
$-1.27
Dividend yield
—
52W range
$1 – $4
Volume
3.0M
C4 Therapeutics Inc (CCCC) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
+8.0%
Last 4 quarters
Revenue YoY growth
+112.8%
Most recent quarter
EPS YoY growth
+63.3%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+7.5%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+16.3%
2026-02-25
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-25 | $-0.18 | +37.6% | $2.39 | $2.78 | +16.3% |
| 2025-11-06 | $-0.44 | -7.3% | $2.37 | $2.34 | -1.3% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.29 | $-0.18 | +37.6% | $11.02M | +112.8% |
| 2025-09-30 | $-0.41 | $-0.44 | -7.3% | $11.23M | -26.9% |
| 2025-06-30 | $-0.40 | $-0.37 | +7.5% | $6.46M | -46.2% |
| 2025-03-31 | $-0.35 | $-0.37 | -5.7% | $7.24M | +138.2% |
| 2024-12-31 | $-0.45 | $-0.49 | -8.8% | $5.18M | +58.8% |
| 2024-09-30 | $-0.38 | $-0.35 | +7.9% | $15.36M | +38.7% |
| 2024-06-30 | $-0.37 | $-0.26 | +29.7% | $12.01M | +350.7% |
| 2024-03-31 | $-0.35 | $-0.41 | -17.1% | $3.04M | — |
| 2023-12-31 | $-0.68 | $-0.70 | -2.9% | $3.26M | — |
| 2023-09-30 | $-0.66 | $-0.52 | +21.2% | $11.07M | — |
| 2023-06-30 | $-0.69 | $-0.73 | -5.8% | $2.66M | — |
Frequently asked questions
Has C4 Therapeutics Inc beaten earnings estimates?
C4 Therapeutics Inc has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of +8.0% over the last 4 quarters.
How does CCCC stock react to earnings?
CCCC stock has moved an average of +7.5% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is C4 Therapeutics Inc's revenue growth rate?
C4 Therapeutics Inc reported year-over-year revenue growth of +112.8% in its most recent quarter, with EPS growing +63.3% year-over-year.